ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Friday.

Separately, Zacks Investment Research raised ImmunoCellular Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a report on Thursday, August 25th.

ImmunoCellular Therapeutics (NYSEMKT:IMUC) opened at 0.0945 on Friday. ImmunoCellular Therapeutics has a 12-month low of $0.08 and a 12-month high of $0.53. The company’s market cap is $12.09 million. The stock’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.18.

ImmunoCellular Therapeutics (NYSEMKT:IMUC) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Equities research analysts anticipate that ImmunoCellular Therapeutics will post ($0.20) EPS for the current year.

An institutional investor recently raised its position in ImmunoCellular Therapeutics stock. Sabby Management LLC boosted its position in ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC) by 0.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 4,452,128 shares of the company’s stock after buying an additional 40,757 shares during the period. Sabby Management LLC owned approximately 4.78% of ImmunoCellular Therapeutics worth $1,025,000 as of its most recent filing with the SEC.

ImmunoCellular Therapeutics Company Profile

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Stock Ratings for ImmunoCellular Therapeutics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd. and related stocks with our FREE daily email newsletter.